Fig. 1 | Scientific Reports

Fig. 1

From: AAV-mediated co-expression of an immunogenic transgene plus PD-L1 enables sustained expression through immunological evasion

Fig. 1

Screening of tissue-specific firefly luciferase expression, targeting liver and muscle tissues. (A) Screening assay vector construct design. (B) Liver targeting via AA8-AAT/APOE-Luc IV dosing, with bioluminescence imaging at weeks 1 and 3. (C) Skeletal and cardiac muscle targeting via AAV8-MHCK7-Luc IV or AAV9-MHCK7-Luc IV, with bioluminescence imaging at weeks 1 and 3. (D) Quantification of bioluminescence from mice treated with AA8-AAT/APOE-Luc IV at weeks 1 and 3. (E) Ex vivo tissues from animals treated with AA8-AAT/APOE-Luc IV at week 3. (F) Quantification of bioluminescence from mice treated with AAV8-MHCK7-Luc IV or AAV9-MHCK7-Luc IV at weeks 1 and 3. (G) Ex vivo tissues from animals treated with AAV8-MHCK7-Luc IV or AAV9-MHCK7-Luc IV at week 3. Firefly luciferase abbreviated as “Luc” in figure. Statistics, GraphPad Prism, two-way ANOVA with Tukey’s multiple comparison test, n = 5, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page